APA (7th ed.) Citation

C, K., H, I., K, N., H, S., K, T., N, T., . . . N, B. (2025). The FSTL1-DIP2A axis is a significant biomarker for predicting anti-PD1 therapeutic efficacy in advanced gastric cancer. Cancer immunology, immunotherapy : CII, 74(12), 379. https://doi.org/10.1007/s00262-025-04239-1

Chicago Style (17th ed.) Citation

C, Kudo-Saito, et al. "The FSTL1-DIP2A Axis Is a Significant Biomarker for Predicting Anti-PD1 Therapeutic Efficacy in Advanced Gastric Cancer." Cancer Immunology, Immunotherapy : CII 74, no. 12 (2025): 379. https://doi.org/10.1007/s00262-025-04239-1.

MLA (9th ed.) Citation

C, Kudo-Saito, et al. "The FSTL1-DIP2A Axis Is a Significant Biomarker for Predicting Anti-PD1 Therapeutic Efficacy in Advanced Gastric Cancer." Cancer Immunology, Immunotherapy : CII, vol. 74, no. 12, 2025, p. 379, https://doi.org/10.1007/s00262-025-04239-1.